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An in vivo ultrahigh ﬁeld 14.1 T 1H-MRS study
on 6-OHDA and a-synuclein-based rat models
of Parkinson’s disease: GABA as an early
disease marker
P. G. Counea†, M. Craveirob†, M. N. Gauglera, V. Mlynárikb, B. L. Schneidera,
P. Aebischera and R. Gruetterb,c,d*
The detection of Parkinson’s disease (PD) in its preclinical stages prior to outright neurodegeneration is essential to
the development of neuroprotective therapies and could reduce the number of misdiagnosed patients. However,
early diagnosis is currently hampered by lack of reliable biomarkers. 1H magnetic resonance spectroscopy (MRS)
offers a noninvasive measure of brain metabolite levels that allows the identiﬁcation of such potential biomarkers.
This study aimed at using MRS on an ultrahigh ﬁeld 14.1 T magnet to explore the striatal metabolic changes
occurring in two different rat models of the disease. Rats lesioned by the injection of 6-hydroxydopamine (6-OHDA)
in the medial-forebrain bundle were used to model a complete nigrostriatal lesion while a genetic model based on
the nigral injection of an adeno-associated viral (AAV) vector coding for the human a-synuclein was used to model
a progressive neurodegeneration and dopaminergic neuron dysfunction, thereby replicating conditions closer to
early pathological stages of PD. MRS measurements in the striatum of the 6-OHDA rats revealed signiﬁcant decreases
in glutamate and N-acetyl-aspartate levels and a signiﬁcant increase in GABA level in the ipsilateral hemisphere
compared with the contralateral one, while the aSyn overexpressing rats showed a signiﬁcant increase in the GABA
striatal level only. Therefore, we conclude that MRS measurements of striatal GABA levels could allow for the
detection of early nigrostriatal defects prior to outright neurodegeneration and, as such, offers great potential as a
sensitive biomarker of presymptomatic PD. Copyright © 2012 John Wiley & Sons, Ltd.
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INTRODUCTION
The availability of sensitive and reliable biomarkers is critical for the
development of therapeutic approaches to protect brain cells from
neurodegenerative diseases. Early detection of Parkinson’s disease
(PD), the second most common neurodegenerative disease, could
open avenues for preventive approaches and alternatives to
current treatments that offer only temporary symptomatic relief.
Indeed, PD diagnosis prior to the death of a substantial portion
of nigral dopaminergic neurons is essential for developing strate-
gies aimed at slowing down disease progression. Unfortunately,
the pathology progresses in nigrostriatal neurons before initial
motor symptoms appear, which occurs when at least 50% of
striatal dopamine and most nigral neurons have already been
lost (1). It has been shown that non-motor perturbations such as
impaired olfaction, sleep disorders, gastrointestinal and urinary
abnormalities, cardiovascular dysfunction, depression and mood
disorders can precede the appearance of typical motor symptoms
(2). Although this pre-motor syndrome may represent an
opportunity to identify patients at risk of developing PD, efﬁcient
diagnosis requires speciﬁc early markers of nigrostriatal pathology.
Animal models that mimic human pathology as closely as
possible are likely to contribute to the search for disease
markers. Until now, mammalian models for PD have been mainly
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based on the use of neurotoxins such as 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine (MPTP) and 6-hydroxydopamine (6-
OHDA), which lead to selective and extensive loss of nigrostriatal
dopaminergic innervation. However, their mechanisms of action
are unlikely to faithfully replicate either molecular or progressive
courses of the disease. The precise aetiology of PD remains
largely unknown but there is clear evidence that the protein
a-synuclein (aSyn) plays a causal role in some familial variants.
aSyn may also play a role in the most common idiopathic form
of PD (3–5). The implication of the aSyn gene in PD has led to
the development of animal models based on adeno-associated
viral vectors (AAV) to selectively express human aSyn in adult
nigral neurons (6). Over several months, injected rats displayed
nigral degeneration similar to early phases of PD with loss of
striatal terminals and nigral cell bodies, reduced dopamine
transmission and mild motor impairments.
Magnetic resonance spectroscopy (MRS) offers a noninvasive
method for investigating animal models to identify potential
disease markers. Proton MRS studies have been conducted on
toxin-based PD models in monkeys, rats and mice (7–13), and
reported changes in striatal levels of several metabolites such
as g-aminobutyric acid (GABA), glutamate (Glu), N-acetyl-
aspartate (NAA) and lactate (Lac) have been attributed to the
loss of nigro-striatal dopaminergic ﬁbres. In addition, MRS stud-
ies have reported variations in NAA levels in the frontal cortex
of 6-OHDA lesioned rats (14) and PD patients (15).
This study aimed at using 14.1 T proton MRS to analyze striatal
and cortical levels of metabolites in two unilateral rat models of
PD. The use of ultrahigh 14.1 T provided a sensitive detection
and quantiﬁcation of about 20 brain metabolites. A complete
lesion of the nigrostriatal pathway with 6-OHDA served as a
model for advanced neuronal loss, while the progressive
degeneration induced by aSyn replicated conditions closer to
early pathological stages. Moreover, the unilateral lesion in both
models allowed the use of the contralateral hemisphere as an
internal control for each animal.
MATERIAL AND METHODS
Animal procedures
Nine-week-old female adult Sprague-Dawley rats (Charles River
Laboratories, Wilmington, MA, USA) weighing 180-200 g were
housed in cages with a 12 h light/dark cycle and ad libitum ac-
cess to food and water. Protocols conformed to Swiss legislation
and the European Community Council directive (86/609/EEC) for
the care and use of laboratory animals.
6-OHDA model
Six rats received injections of 6-OHDA in the medial forebrain
bundle (MFB). The animals were anesthetized with a mixture of
xylazine/ketamine and placed in a stereotactic frame (David Kopf
Instruments, Tujunga, CA, USA). Four ml of a 5mg/ml solution of
6-OHDA in ascorbic-saline (1mg/ml ascorbic acid in 0.9% saline)
(Sigma-Aldrich Chemie GmbH, Buchs, Switzerland) were injected
in the right brain hemisphere using a 10-ml Hamilton syringe
(Sigma) with a 34-gauge blunt tip needle connected to an
automatic pump (CMA Microdialysis AB, Solna, Sweden). The
following coordinates were used to target the MFB: antero-
posterior – 1.9mm and medio-lateral + 1.9mm relative to
bregma, and dorso-ventral – 7.2mm relative to skull surface.
The injection speed was set at 1 ml/min. The needle was left in
place for an additional three min before being slowly withdrawn.
Three sham animals received 4ml ascorbic-saline (1mg/ml
ascorbic acid in 0.9% saline) following the same procedure.
MRS measurements were performed in the striatum prior to
6-OHDA injection and in the striatum and primary motor cortex
(M1) three weeks later following the same protocol.
AAV-aSyn model experiment
Recombinant pseudotyped rAAV2/6 were produced, puriﬁed
and titrated as previously described (16). Relative infectious titers
were determined by real-time PCR on total DNA extracts from
AAV-transduced HEK293T cells. Five rats received 2.8 x 107 TU
of AAV2/6-pgk-aSyn-WT and six rats received undiluted control
non-coding vector whose injected dose was estimated to be
1.5 x 107 TU. Using an injection setup similar to the 6-OHDA
injections, the substantia nigra pars compacta (SNpc) was
targeted using the following coordinates: anterio-posterior –
5.2mm and medio-lateral – 2.0mm relative to bregma, and
dorso-ventral – 7.8mm relative to skull surface. Two ml of virus
preparation was injected in the right brain hemisphere at a
speed of 0.2 ml/min. The needle was left in place for an additional
ﬁve min before being slowly withdrawn. The animals underwent
NMR measurements in the striatum 12weeks after the injection.
NMR measurements and post-processing
All experiments were carried out on an animal 26-cm diameter
horizontal-bore 14.1 T magnet (Magnex Scientiﬁc, Oxford, UK)
interfaced to a Varian INOVA console (Varian Inc., Palo Alto, CA,
US). The magnet was equipped with an actively shielded
12-cm-diameter gradient (400 mT/m in 120msec; Magnex
Scientiﬁc, Oxford, UK). A custom-made quadrature surface coil
consisting of two geometrically decoupled 14-mm diameter
single loops was used as a transceiver.
Rats were anesthetized with 3% isoﬂurane combined with a
mixture of air and O2, stereotaxically ﬁxed with two earpieces
and a bite bar in a holder and placed at the isocenter of the
magnet. Throughout the experiment, rats were kept anesthetized
with 1.5-2% isoﬂurane. Breathing and temperature parameters
were monitored with an MR-compatible monitor system (model
1025; SA Instruments, Stony Brook, NY, USA) and animal
temperature was maintained at 38 C by circulating warm water.
For localization of the volume of interest (VOI), T2-weighted
multislice images were acquired using a fast spin echo technique
with a ﬁeld of view of 25 x 25mm2, 256 x 256 data matrix, 0.8mm
slice thickness, effective TE = 52ms and TR= 5000ms. Localized
1H-MR spectra were acquired in a 27-ml (3 3 3mm3) volume
from the striatum and in a 13.6-ml (1.7 2 4mm3) volume from
the primary motor cortex (M1) of the right hemisphere using
the SPECIAL sequence (17) with TE = 2.8ms and TR= 4000ms
combined with outer volume suppression and VAPOR water
suppression (18). The centre of the voxel located in the primary
motor cortex was positioned 0.5mm posterior and 1.5mm right
(or left for the left hemisphere) from the bregma and -1.5mm
from the skull surface. Voxel coordinates were determined with
the help of the Paxinos and Watson atlas (19). Two-hundred
and forty averages were acquired for optimal SNR. Static
magnetic ﬁeld homogeneity was adjusted with an EPI version
of FASTMAP (20) using ﬁrst- and second-order shims. As internal
controls for the injected hemispheres, spectra were also acquired
in the contralateral hemisphere of each animal. Contralateral and
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injected hemispheres were randomly scanned to avoid any tem-
poral bias due to anaesthesia. Absolute quantiﬁcation was per-
formed using the water signal as an internal reference. Water
spectra were acquired with the same parameters without water
suppression and with eight averaging scans.
In vivo 1H-MR spectra were processed as previously described
(21), frequency drift corrected, summed and eddy-current
compensated using the water signal from the same VOI.
Experimental spectra were ﬁtted with LCModel software (22)
using a simulated basis set of metabolites and a spectrum of
macromolecules measured in vivo using an inversion recovery
sequence (21). The metabolite basis set included alanine (Ala),
ascorbate (Asc), aspartate (Asp), creatine (Cr), myo-inositol
(myo-Ins), GABA, glucose (Glc), glutamine (Gln), Glu, glycine
(Gly), glycerophosphocholine (GPC), glutathione (GSH), Lac,
NAA, N-acetyl-aspartyl-glutamate (NAAG), phosphocholine
(PCho), phosphocreatine (PCr), phosphorylethanolamine (PE),
scyllo-inositol (Scyllo) and taurine (Tau).
Immunohistological analysis
Rats were sacriﬁced and tissues processed as described
previously (23). Striatal slices (25-mm thick) were quenched with
0.1% phenylhydrazine in PBS at 37 C for 1 h, blocked for 2 h at
room temperature, incubated overnight at 4 C with primary
antibody TH (tyrosine hydroxylase, rabbit IgG, 1:500, AB152)
(Chemicon, Millipore AG, Zug, Switzerland) then incubated 2 h
at room temperature in a biotinylated goat anti-rabbit antibody
(1:200; Vector Laboratories). Sections were then incubated with
avidin-biotin-peroxidase complex (Vector Laboratories Ltd,
Peterborough, UK) for 30min at room temperature and revealed
with 3,3’-diaminobenzidine (DAB) solution (Sigma) before
mounting on glass slides with Eukitt medium.
Densitometric analysis of striatal dopaminergic innervation
Striatal dopaminergic innervation was analyzed by measuring
the optical density (OD; integrated density of gray pixel values
corrected for non-speciﬁc background) of TH immunoreactivity
on 16 striatal sections. Sections were scanned using an Epson
Perfection V750 Pro scanner and OD of the striatum was
analyzed using ImageJ software (free NIH software: http://
rsbweb.nih.gov/ij/). Results are expressed as the percentage of
TH immunoreactivity loss with respect to the contralateral non-
injected hemisphere.
Stereological quantiﬁcation of dopaminergic neuronal loss
Midbrain 40-mm thick coronal sections stained for TH were
analyzed according to optical fractionator method using
Stereo Investigator v.8 software (MBF Biosciences, Magdeburg,
Germany). TH positive neurons were counted in every sixth
section covering the entire SNpc at 60x magniﬁcation (total 12
sections per animal). We applied the following criteria: grid size,
180 200mm; counting frame, 75 75mm; guard zones, 2mm.
Gunderson coefﬁcient of error (m= 1) was inferior to 0.1 for each
animal. Since average tissue thickness was measured in both
hemispheres for each slice prior to counting, the total number
of TH-positive neurons was calculated according to estimated
total by mean measured thickness.
Statistical analyses
Immunohistological data statistical analysis was performed using
a paired Student’s t-test comparing total TH signal ODs from
both hemispheres. Statistical analysis of MRS results was per-
formed within each group using a paired Student’s t-test, which
allows for a comparison between the contralateral and ipsilateral
hemisphere in each animal to establish signiﬁcant changes in
the neurochemical proﬁle of the affected hemisphere compared
to the healthy one. Differences in metabolite concentration
between both hemispheres within each animal of the group
were considered signiﬁcant when p< 0.05.
To determine whether potential metabolite level asymmetries
between both hemispheres were indeed due to metabolite
alterations in the ipsilateral hemisphere and therefore to exclude
effects on the results of compensation phenomena between
hemispheres, metabolite levels within each hemisphere pre-
and post-injection were also compared for metabolites
expressing signiﬁcant asymmetries. Signiﬁcance of metabolite
alteration within each hemisphere between pre- and post-
injection stages was determined using a paired Student’s t-test.
RESULTS
Typical in vivo proton spectra obtained in the striatum and
primary cortices of the examined animals are depicted in
Figure 1. After shimming, the typical linewidth of the water
resonance was 15-18Hz in the striatum and 18-22Hz in the
cortex. 1H-MR spectra were obtained in both regions with a
typical SNR of 30 2 (measured on the NAA singlet). All
metabolites included in the basis set except Scyllo were
quantiﬁed with Cramér-Rao lower bounds (CRLB) lower than
20% in the striatum. In the cortex, Scyllo, Gly, PCho and
Ala, which are among the least abundant metabolites, were
quantiﬁed with CRLB between 20 and 80%. All other metabolites
were quantiﬁed with CRLB lower than 20%. In both brain regions,
the metabolites of interest (NAA, GABA, Glu) were quantiﬁed
with CRLB lower than 5-10%.
6-OHDA experiment
After the ﬁrst MRS scan of the striatum as reference, rats received
a 6-OHDA or an ascorbic-saline control injection (sham) in the
right medial forebrain bundle. Three weeks after the injection,
rats were scanned a second time then sacriﬁced and their
brain processed for immunohistochemistry. Analysis of the
optical density of the striatal TH staining revealed that all
animals injected with 6-OHDA displayed a nearly total striatal
denervation, as demonstrated by striatal TH optical density
analysis (average decrease = 96.8 0.7% compared to the non-
injected side, Fig. 2A) while sham operated animals displayed
only marginal innervation loss (average = 6.7 1.4% decrease
compared with the non injected side, Fig. 2A). Stereological
analysis of the TH positive nigral neurons conﬁrmed the extent
of the nigro-striatal denervation induced by 6-OHDA injection
with an average loss of 88.8 4.4% compared to the non-
injected side (Fig 2B). In comparison, sham operated animals
displayed only marginal neuronal loss (average loss= 13.1 11.0%
compared to the non-injected side).
Comparison of concentration ratios between lesioned and
control striata in the 6-OHDA-treated animals showed a signiﬁcant
increase in GABA concentration (+ 20 5%) while NAA and Glu
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concentrations were signiﬁcantly decreased (- 7 2% and –
6 1%, respectively) in the lesioned striatum (Fig. 3C). Comparison
of pre- and post-injection levels performed for the metabolites
within each hemisphere demonstrated that signiﬁcant changes
were detected in the ipsilateral striatum while no signiﬁcant
changes were detected between pre- and post-injection stages
in the contralateral striatum, allowing for exclusion of any potential
effect due to compensation phenomena on the results. No signiﬁ-
cant differences were observed between the right and left striata
in the same animals in the reference scan; i.e. prior to 6-OHDA
injections (Fig. 3A). Cortical measurements did not lead to any
signiﬁcant changes (Fig. 3D).
Alpha-synuclein experiments
Animals received an intra-nigral stereotactic injection of either
an AAV vector coding for human aSyn or a control non-coding
vector. Twelve weeks after the injection, rats were scanned then
sacriﬁced and their brain processed for immunohistochemistry.
Immunostaining for TH revealed that all aSyn overexpressing
animals displayed a moderate striatal denervation on the
injected side (average decrease of 26.1 3.5% compared to
the non-injected side, Fig. 2C). Stereological analysis of the TH
positive nigral neurons conﬁrmed the extent of the nigro-striatal
denervation induced by aSyn over-expression, with an average
loss of 27.1 4.6% compared to the non-injected side (Fig 2D).
Although expression of human aSyn produced only a moderate
axon loss in these conditions, the extent of dopaminergic
denervation was clearly different from the animals injected with
the empty control vector, with an average loss of 9.6 1.5%
compared to the non-injected side (Fig. 2C).
Remarkably, MRS of the striatum of the animals overexpressing
aSyn revealed a signiﬁcant increase in GABA content (+ 12 1%)
compared to the non-injected side. We did not observe any other
signiﬁcant metabolite variation, including NAA, glutamate and
lactate (Fig 4A). Control animals injected with the empty vector
did not show any signiﬁcant difference in any of the metabolites
tested (Fig 4B).
DISCUSSION
This study showed that the two investigated PD models character-
ized by different levels of neurodegeneration expressed different
metabolite alteration patterns but shared an increase in GABA
striatal levels. These results were obtained with a 14.1 T ultrahigh
ﬁeld magnet that provided a highly precise measurement of
metabolite concentrations in agreement with striatal and cortical
values of healthy rat brain regions reported in previous 1H-MRS
studies (24,25). Moreover, the increased spectral resolution at
14.1 T was sufﬁcient to partially resolve the GABA resonances.
We investigated the effect of nigro-striatal neuron degeneration
within the striatum. Indeed, PD is characterized by the degenera-
tion of the dopaminergic neurons of the SNpc, which is part
of deep brain nuclei and is therefore poorly accessible to
current MRS procedures. However, the nigral neurons are mostly
projecting in the striatum, a large and anatomically homogeneous
structure that can be easily measured by MRS. Therefore, nigro-
striatal denervation consequences were investigated by
measurement of the striatal concentrations of brain metabolites.
Moreover, while measurements have been previously conducted
in the striata of MPTP mice using a 9.4 T magnet, no previous
proton MR spectroscopic study has been performed on a PD rat
model at such a high ﬁeld. Similarly, no measurements of GABA
levels using proton MR spectroscopy have been reported in a
6-OHDA model. In addition, the advantage of both models used
in our study was that unilateral injections allowed using the
contralateral hemisphere as an internal control for each animal.
To interpret the results of our study, it is important to consider
the difference between the two models of PD. First described in
1968 (26), intra-nigral injection of 6-OHDA is known to induce an
almost complete anterograde degeneration of the dopaminergic
nigrostriatal system. Even though it has become a common
A
B
C
Figure 1. Representative spectra acquired in the ipsilateral striatum of a 12
weeks old rat injected with ascorbic saline (A) or with 6-OHDA (B), 3 weeks
after injection, and representative spectrum acquired in the ipsilateral
primary motor cortex region of a rat injected with 6-OHDA, 3 weeks after
injection (C). The spectra are displayed with a Gaussian function apodisation
(gf =0.2). VOI in both brain regions (333mm3 in striatum and 1.724
mm3 in primary motor cortex) are represented on T2-weighted images.
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PD model, the exact mechanism by which 6-OHDA induces
dopaminergic cell death has not been entirely elucidated.
However it is known to involve increased oxidative stress (27)
and impairment of the cellular respiratory machinery (28), and
6-OHDA injections in the nigro-striatal system lead to an acute
and nearly total striatal denervation that typically develops over
7 days. Typically, 6-OHDA unilaterally treated animals present
strongly asymmetrical motor behaviour in both drug induced
and spontaneous testing within three weeks post injection. As
such, injection of 6-OHDA in the medial-forebrain bundle aims
to mimic end-stage PD by replicating the selective loss of
the nigral neurons, which is considered a pathological signature
responsible for the most prominent motor symptoms of the
disease.
In contrast, our aSyn-based model was developed to induce
a functional perturbation in the dopaminergic nigrostriatal
transmission. Using an AAV-vector, human aSyn was over-
expressed unilaterally in the nigral dopaminergic neurons of
the rats. Over twelve weeks, over-expression of human aSyn
generated only moderate nigral degeneration. However, the
surviving neurons displayed functional impairments leading to
decreased striatal dopamine release (6). Despite a signiﬁcant
proportion of surviving nigral neurons in the hemisphere
injected with aSyn AAV vector, aSyn overexpressing animals
displayed motor deﬁcits in the form of asymmetrical motor
behaviour in both apomorphine-induced rotametry and cylinder
test. In contrast with 6-OHDA induced motor impairment,
aSyn-induced deﬁcit appeared progressively over several weeks
and was of moderate extent (6). Overall, aSyn overexpressing
rats presented motor impairments that could reﬂect an early
stage of PD. Therefore, this model system appears particularly
suited for a rational search of sensitive biomarkers of initial
pathological changes. (Tables 1 and 2)
We propose that changes in striatal NAA and GABA levels
reﬂected the difference in the denervation extent induced by
these two models for the following reasons. First, NAA is a highly
abundant brain metabolite almost exclusively present in
neurons. Synthesized in neuronal mitochondria, it is therefore
widely accepted as a marker of neuronal integrity (29,30).
Moreover, reduced NAA levels have been reported in many
neuropathological conditions including Alzheimer’s disease,
multiple sclerosis and cerebral ischemia (31–33). Indeed, the
nearly total dopaminergic denervation observed in the striatum
of the 6-OHDA injected animals was paralleled by lower NAA
levels in the ipsilateral striata. In contrast, the aSyn overexpres-
sing rats within experimental error did not display any signiﬁcant
difference in NAA. One hypothesis is that, in the absence of a
signiﬁcant effect of aSyn on mitochondrial function consistent
with the mild striatal denervation observed, NAA levels would
not be signiﬁcantly affected in contrast with conditions of severe
nigro-striatal denervation such as in the 6-OHDAmodel. It is inter-
esting to note that lower NAA levels have been previously
reported in MPTP models of rat, mouse and monkey using MRS
(34,35). However, the only study conducted on 6-OHDA-lesioned
rats did not report any signiﬁcant variation in NAA levels (11).
Experimental precision could therefore be critical in detecting
Figure 2. (A) Injection of 6-OHDA led to a nearly complete denervation of the striatum (96.8% of TH signal loss); n=6 for the 6-OHDA group, n=3 for the
sham group, **p< 0.01 compared with sham animals by Student’s t-test. (B) Injection of 6-OHDA led to a nearly complete degeneration of the nigral TH
positive neurons (88.8% of cell loss); n=6 for the 6-OHDA group, n=3 for the sham group, **p< 0.01 compared with sham animals by Student’s t-test
(C) 12 weeks post-injection, a-synuclein over-expressing animals display a modest (26.1% of TH signal loss) but signiﬁcant striatal denervation; n=5 for
the aSyn group and n=6 for the empty vector control group. (D) 12 weeks post-injection, a-synuclein over-expressing animals display a modest (27.1% of
cell loss) but signiﬁcant degeneration of the nigral TH positive neurons; n=5 for the aSyn group and n=6 for the empty vector control group. Data are
presented as group mean standard error of the mean. Signiﬁcance ***p< 0.001, **p< 0.01, *p> 0.05, compared with control animals by Student’s t-test.
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small variations in NAA levels such as the 7% decrease observed
in the present study.
Second, we observed that both 6-OHDA-induced total
denervation and aSyn-induced progressive degeneration led to
20% and 12% increases in measured striatal GABA concen-
trations, respectively. Striatal neurons receiving dopaminergic
afferents from the SNpc are GABAergic spiny neurons and it is
established that nigral dopaminergic neurons exert a tonic
inhibitory control on these GABAergic neurons through D2
receptors (36). Therefore, dopaminergic denervation is antici-
pated to cause hyperactivity in this subset of neurons. Evidence
for such GABAergic hyperactivity can be found in experiments
on 6-OHDA-lesioned rats and MPTP-treated-monkeys: striatal
denervation leads to a striatal increase in glutamic acid
decarboxylase (GAD) mRNA levels and GAD activity (37–39).
Moreover, microdialysis studies in 6-OHDA-lesioned rats and
MPTP-treated monkeys also showed an increase in extracellular
GABA levels following nigrostriatal degeneration (13,37–40). A
decrease in dopamine neurotransmission due to functional
impairment of the nigral neurons could also affect striatal
activity, and therefore GABA levels, independently from nigro-
striatal denervation. It has been demonstrated that in conditions
of overexpression, aSyn expression can impair neurotransmitter
release (41). Such an impairment of dopamine release has been
demonstrated in the rat model used in the present study (6).
Therefore, the variations in GABA levels observed in the aSyn
model could result from a combination ofmild neurodegeneration
and functional defect in the remaining nigrostriatal neurons.
In humans, functional impairments of dopamine transmission
can represent an initial step in a vicious circle leading to
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Figure 3. Metabolite concentration measured in the contralateral and ipsilateral striatum of pre-injected animals (n = 6) (A) and injected animals 3
weeks after an injection of ascorbic saline solution (n= 3) (B) or 6-OHDA (n = 6) (C), and cortices metabolite concentration measurements 3 weeks after
6-OHDA injection (n = 6) (D). Error bars represent the standard error of the mean. Signiﬁcant differences in metabolite level between both hemispheres
are indicated with *(p< 0.05) and **(p< 0.01) and results are summarized in Table 1.
Table 1. 6-OHDA model. Measured metabolite concentration ratio of ipsilateral (right) and contralateral (left) (Cright/Cleft)
hemispheres in the striatum before and 3weeks after a 6-OHDA or ascorbic-saline injection and in the primary motor cortex
3weeks after a 6-OHDA injection. Data are presented as group mean standard error of the mean. Signiﬁcance of the asymmetry
between both hemispheres in each group was determined with a paired Student’s t-test and is displayed with *p< 0.05, **p< 0.01.
Striatum before 6-OHDA
injection (n= 6)
Striatum after 6-OHDA
injection (n=6)
Striatum after ascorbic-saline
injection (n= 3)
Cortex after 6-OHDA
injection (n= 6)
GABA 1.07 0.03 1.20 0.05** 0.99 0.05 1.27 0.14
NAA 0.99 0.02 0.93 0.02* 0.91 0.04 1.05 0.03
Glu 1.01 0.02 0.94 0.01** 0.95 0.04 1.02 0.05
Lac 1.25 0.13 1.12 0.12 1.05 0.09 1.23 0.27
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neurodegeneration. Consequently, measurements of striatal GABA
levels could allow for the detection of early pathologic nigrostriatal
defects prior to subsequent extensive neurodegeneration and
appearance of motor symptoms.
The results obtained in the present study on GABA striatal
levels in a 6-OHDA rat model conﬁrm an increase reported in
MPTP-treated mice (8). In addition, this increase in GABA
appears to be detectable in the aSyn model expressing an early
stage of nigrostriatal defects, and could therefore represent a
sensitive marker of neuronal dysfunction due to nigrostriatal
degeneration. Moreover, GABA seems to be a more sensitive
marker of early neuronal defects due to mild nigrostriatal
denervation than NAA, which is expected to decrease as a
function of neuronal degeneration. Indeed, dopaminergic
terminals represent only a small fraction of the complex striatal
neuropil, and even an almost complete loss of dopaminergic
axons produced by 6-OHDA intoxication only marginally impacts
striatal metabolism, yet in a more profound manner than aSyn
over-expression.
On the other hand, of the potentially implicated metabolites
such as Glu and Lac, we detected a 6% decrease in Glu
concentration in the 6-OHDA model. A previous study using
1 H-MRS in the same model did not ﬁnd any signiﬁcant alteration
in glutamate concentration (11). However, the 6% decrease we
report is inferior to the 16% detection threshold of glutamate
concentration precision shown by Kickler et al. and could be
detected due to the increased precision provided by the 14.1 T
magnet. No signiﬁcant variation of glutamate concentration
was observed in the aSyn model, indicating that such
glutamate up-regulation may not be detectable at an early stage
of neurodegeneration.
A signiﬁcant increase in striatal lactate concentration has been
reported in a previous MRS study of a 6-OHDA lesion (11). In our
study, neither 6-OHDA nor the aSyn based model displayed
increased striatal lactate concentration. Interestingly, lactate
levels appeared highly variable between hemispheres even prior
to any lesion, consistent with isoﬂurane having dose- and time-
dependent effects on brain lactate levels (42). Exposure to
isoﬂurane together with the applied protocol randomizing
hemisphere scanning likely explains the observed variability.
Additional investigations addressing the role of anaesthesia
conditions will be necessary to further characterize potential
changes in lactate.
Finally, measurements performed in the cortex of the 6-OHDA
lesioned rats did not show any signiﬁcant concentration
changes, though a trend to increased GABA was observed.
However, cortex measurements for this metabolite showed a
higher variability compared to the striatum. Consequently, the
cortex measurements, in contrary to the striatum measurements,
did not lead to any signiﬁcant metabolite alteration and indicate
that the striatum, which is the direct projection of the nigral
neurons, might be a better investigative target for metabolite
alterations due to nigrostriatal denervation.
CONCLUSION
Striatal GABA concentrations could serve as an early marker of
Parkinson’s disease measurable through noninvasive MRS. The
availability of such a marker can serve as a basis for improving
the diagnosis of PD and open perspectives for future neuropro-
tective approaches.
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Figure 4. Metabolite concentration measured in the contralateral and
ipsilateral striatum of injected animals with AAV vectors coding for
a-synuclein (n=5) (A) and animals of the control group injected with a
non-coding vector (n=6) (B). Error bars represent the standard error of the
mean. Signiﬁcant differences in metabolite level between both hemispheres
are indicated with **(p< 0.01) and results are summarized in Table 2.
Table 2. AAV-aSyn model. Measured metabolite concentra-
tion ratio between right and left hemispheres in the striatum
after an injection of AAV vectors coding for WT aSyn and after
an injection of non coding vectors, 12weeks after injection in
the SNpc. Data are presented as group mean standard error
of the mean. Signiﬁcance of the asymmetry between both
hemispheres in each group was determined with a paired
Student’s t-test and is displayed with **p< 0.01.
WT aSyn (n = 5) Non-coding vector (n = 6)
GABA 1.12 0.01** 1.03 0.08
NAA 0.99 0.02 0.97 0.03
Glu 1.00 0.02 0.98 0.02
Lac 1.26 0.12 1.01 0.08
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